BioCardia (STU:6JU0) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 02, 2026)


STU:6JU0 BioCardia Inc STU:6JU0
21 GF Score
Price €0.27
GF Value €0.01
! 1 Warning Sign
View Full Analysis

What is BioCardia Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BioCardia's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:6JU0 vs GRTX, CELU, KTTA: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, BioCardia's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCardia Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BioCardia's Margin of Safety % (DCF Earnings Based) falls into.


STU:6JU0
21GF Score
BioCardia Inc STU:6JU0
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioCardia (STU:6JU0) Overvalued in 2026?

Based on GuruFocus' analysis, BioCardia stock appears to be overvalued. The current stock price of €0.27 is trading 2600% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:6JU0:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.01 vs. price of €0.27 (2600% above fair value)
  • GF Score™: 21/100 with 1 warning sign

No single metric tells the full story. See the STU:6JU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCardia Business Description

Other Exchanges BCDA:USA
Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
21GF Score

Get the complete analysis for STU:6JU0

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.01
GF Value